For weight management, NICE has published technology appraisals for specific GLP-1 agents (semaglutide/Wegovy and liraglutide/Saxenda)
In the UK, hydroxocobalamin is the preferred licensed form for intramuscular injection
Many individuals continue GLP-1 medications long-term to help maintain results
Figure 1: Reimbursement of Wegovy in commercial plans, February 2024 Source: Clarivate Fingertip Analytics, accessed February 2024 Likely impact of rebating The current highly favorable reimbursement environment for Wegovy is likely tied to extensive rebates offered by Novo Nordisk to payers
A medically supervised plan should focus on function, strength, tissue capacity, and long-term resilience
Single-cell sequencing of human white adipose tissue identifies new cell states in health and obesity